Skip to main navigation Skip to search Skip to main content

Efalizumab, a Human Monoclonal Anti-CD11a Antibody, in the Treatment of Moderate to Severe Crohn’s Disease: An Open-Label Pilot Study

  • Washington University in St. Louis
  • University of Nevada, Reno

Research output: Contribution to journalArticlepeer-review

Original languageAmerican English
JournalDigestive Diseases and Sciences
Volume56
Issue number6
DOIs
StatePublished - Jun 1 2011
Externally publishedYes

Disciplines

  • Immunology and Infectious Disease
  • Medicine and Health Sciences

Cite this